Actively Recruiting

Phase 2
Age: 18Years - 99Years
All Genders
ID07431177

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adults With Non-Segmental Vitiligo Followed by an Extension Period

Led by Novartis Pharmaceuticals · Updated on 2026-06-05

210

Participants Needed

28

Research Sites

85 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of GIA632 in adults aged 18 years and older with non-segmental vitiligo (NSV). This Phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to identify the optimal dose of GIA632 for further testing in a Phase 3 program. The study focuses on assessing how GIA632 affects vitiligo by comparing various doses against a placebo. Participants will receive GIA632 or a placebo during a 48-week core treatment period. The study includes multiple groups receiving different doses of GIA632, each administered over the same time frame. After the core period, an extension phase will assess the longer-term safety and effectiveness of the treatment. Throughout the study, participants will undergo regular assessments, including measurements of vitiligo severity using the Facial Vitiligo Area Scoring Index (F-VASI) and Total body Vitiligo Area Scoring Index (T-VASI) at baseline and multiple intervals up to week 48. Researchers will also evaluate improvements using the Vitiligo Noticeability Scale. Safety and efficacy will be monitored during and after treatment, with the total participation lasting at least 48 weeks during the core and extension periods.

CONDITIONS

Brief Title

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent prior to participation
  • Male or female as assigned at birth, aged 18 years or older at screening
  • Diagnosed with non-segmental vitiligo confirmed by physical examination
  • At least 0.5% body surface area affected on the face and an F-VASI score of 0.5 or higher
  • At least 3% body surface area affected on non-facial areas (excluding hands and feet) with a T-VASI score between 3 and 60
Not Eligible

You will not qualify if you...

  • Unable or unwilling to follow study procedures or complete study questionnaires
  • Presence of segmental or mixed vitiligo, or other skin conditions that interfere with assessments
  • Previous use of biologic drugs targeting IL-15 or IL-15 receptors
  • Previous attempt or completion of depigmentation therapy for non-segmental vitiligo
  • Use of prohibited medications or treatments as defined by the study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 48 weeks

Participants receive GIA632 or placebo during the 48-week core treatment period to assess efficacy and safety.

Multiple visits including baseline and follow-up visits at Week 12, Week 24, Week 36, and Week 48

Extension Period

Duration - Duration not specified

Participants continue to be assessed for longer term safety and efficacy after the core treatment period.

Visit schedule varies during the extension period

Trial Site Locations

Total: 28 locations

1

Cahaba Derm and skin hlth ctr 27

Birmingham, Alabama, United States, 35244

Actively Recruiting

2

MedDerm Associates

San Diego, California, United States, 92103

Actively Recruiting

3

Clinical Trials Research Institute

Thousand Oaks, California, United States, 91320

Actively Recruiting

4

Encore Medical Research

Hollywood, Florida, United States, 33024

Actively Recruiting

5

Miami Derm and Laser Institute

Miami, Florida, United States, 33173

Actively Recruiting

6

Global Clinical Professionals

St. Petersburg, Florida, United States, 33714

Actively Recruiting

7

Dawes Fretzin Clinical Rea Group

Indianapolis, Indiana, United States, 46256

Actively Recruiting

8

Hamzavi Dermatology

Fort Gratiot, Michigan, United States, 48059

Actively Recruiting

9

Revival Research Institute

Troy, Michigan, United States, 48084

Actively Recruiting

10

Skin Specialists PC

Omaha, Nebraska, United States, 68144

Actively Recruiting

11

Las Vegas Dermatology

Las Vegas, Nevada, United States, 89144

Actively Recruiting

12

Equity Medical

The Bronx, New York, United States, 10455

Actively Recruiting

13

Oregon Medical Research Center

Portland, Oregon, United States, 97223

Actively Recruiting

14

International Clinical Research Tennessee LCC

Murfreesboro, Tennessee, United States, 37130

Actively Recruiting

15

Center for Clinical Studies

Houston, Texas, United States, 77030

Actively Recruiting

16

Austin Inst for Clinical Research

Pflugerville, Texas, United States, 78660

Actively Recruiting

17

ACRC Trials

Plano, Texas, United States, 75024

Actively Recruiting

18

Virginia Clinical Research

Norfolk, Virginia, United States, 23507

Actively Recruiting

19

Novartis Investigative Site

Sydney, New South Wales, Australia, 2010

Actively Recruiting

20

Novartis Investigative Site

Waitara, New South Wales, Australia, 2077

Actively Recruiting

21

Novartis Investigative Site

Melbourne, Victoria, Australia, 3000

Actively Recruiting

22

Novartis Investigative Site

Mississauga, Ontario, Canada, L4Y 4C5

Actively Recruiting

23

Novartis Investigative Site

Newmarket, Ontario, Canada, L3Y 5G8

Actively Recruiting

24

Novartis Investigative Site

Toronto, Ontario, Canada, M3H 5Y8

Actively Recruiting

25

Novartis Investigative Site

Québec, Quebec, Canada, G1V 4X7

Actively Recruiting

26

Novartis Investigative Site

Shanghai, China, 200040

Actively Recruiting

27

Novartis Investigative Site

Urayasu, Chiba, Japan, 279-0021

Actively Recruiting

28

Novartis Investigative Site

Kofu, Yamanashi, Japan, 400-8506

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

5

Similar Trials

A Phase 2 Randomized Double-blind Placebo-controlled Study t...

Non-segmental Vitiligo

Actively Recruiting

1 location

A Multicenter, Randomized, Double-blind, Placebo-controlled ...

Non-segmental Vitiligo

Actively Recruiting

1 location

An Open-label Single Center, Proof of Concept Study Evaluati...

Non-segmental Vitiligo

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here